Required by Section 914 of the Food and Drug Administration Amendments Act of 2007, the annual report of the impact of 505(q) petitions and petitions for stay of action issued this last Thursday. This report discussed the number of such petition and describes any delays in approval that such petitions may have caused. The report […]
As we previously reported here and here, December receipts are missing from the update, even though the rest of the December metrics have been updated (see below). Well, they are not really missing (other than in the report), they just have not been figured out by FDA, due to the issues associated with the shutdown […]
Day Two started with a recap of Day One (see post from yesterday here) by Dr. Nancy Snyderman. Day Two kicked off with a session entitled Generics Help Patients, How Can Patients Help Generics. This centered on digital virtual prescribing, digital physician visits, and what’s going on in that space. The panelists described the impact […]
The annual meeting of AAM, Access 2019, is being held in the Hyatt Regency, New Orleans from February 4-6, 2019. The agenda of February 4th involved several sessions to be attended only by the members, including that of Science & Regulatory and Policy Working Group, and the Board Meeting. The Science & Regulatory Team discussed […]
Even with the 35-day government shutdown and the stress that came with it, it appears that OGD has broken the 100 approval action barrier again with what looks like (so far) 102 approval actions posted for January as of February 4th. The data is taken from the FDA All Approvals list here . In the first […]
Each year, the Association for Accessible Medicines (AAM) publishes its report on generic drug savings (here). The data is based on the independent IQVIA organization’s findings. Some interesting findings in the forty-page report are outlined below: 93% of generic prescriptions are filled at $20 or less. The average co-pay of for a generic product covered […]
FDA notes on its User Fee web page (here) that the key date for acceptance of NDAs, BLAs, and ANDAs will be dictated by the first date that FDA could accept fees under the appropriation (after the shut down was over) which is January 28, 2019. The Agency gives the following advice as to how […]
The Drug Price Competition and Patent Term Restoration Act of 1984 requires the FDA to publish a notice of all approved products and their marketing status. The FDA satisfies this requirement by publication of the drug products in the Orange Book; the FDA will publish information in the active section (if the product is currently […]
With 5 working days left in January, and despite the turmoil this month has seen, we stand at 58 Full approvals and 17 Tentative approvals reported on the FDA All Approvals page (here) through January 24, 2019. Looking at the first quarter approvals (October thru December), there were a total of 278 full approvals which, […]
Today, the FDA published its required Activities Reports of the Generic Drugs Program (FY 2019) – FDARA Title VIII, Sections 807 and 805 (here). These reports are published quarterly, as required by law, and outline the following activities: ANDAs subject to priority review, ANDAs with a competitive therapy designation (CTD), and pending suitability petitions (a […]
